PA8807801A1 - Inhibidores de cinesina como productos terapeuticos para el cancer - Google Patents

Inhibidores de cinesina como productos terapeuticos para el cancer

Info

Publication number
PA8807801A1
PA8807801A1 PA20088807801A PA8807801A PA8807801A1 PA 8807801 A1 PA8807801 A1 PA 8807801A1 PA 20088807801 A PA20088807801 A PA 20088807801A PA 8807801 A PA8807801 A PA 8807801A PA 8807801 A1 PA8807801 A1 PA 8807801A1
Authority
PA
Panama
Prior art keywords
inhibitors
cancer
compounds
cinesine
ksp
Prior art date
Application number
PA20088807801A
Other languages
English (en)
Inventor
Abrams Tyna
Barsanti Paul
Duhl David
Faure Michel
A Renhowe Paul
Olga Walter Annette
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40328566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8807801(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PA8807801A1 publication Critical patent/PA8807801A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCIÓN PROPORCIONA NOVEDOSOS COMPUESTOS DE IMIDAZOL QUE INHIBEN LA ACTIVIDAD DE LA PROTEÍNA DE HUSO DE CINESINA(KSP,TAMBIÉN DENOMINADA COMO Eg5).LOS INHIBIDORES DE KSP PUEDEN REDUCIR LA PROLIFERACIÓN CELULAR INDESEADA,Y PROPORCIONAN OTROS EFECTOS TERAPÉUTICOS.LA INVENCIÓN TAMBIÉN PROPORCIONA COMPOSICIONES FARMACÉUTICAS QUE CONTIENE ESTOS COMPUESTOS NOVEDOSOS,Y MÉTODOS PARA UTILIZAR LOS INHIBIDORES DE KSP NOVEDOSOS Y SUS COMPOSICIONES FARMACÉUTICAS PARA TRATAR DIFERENTES TIPOS DE CÁNCERES. LOS COMPUESTOS,COMPOSICIONES Y MÉTODOS DE LA INVENCIÓN SON EN ESPECIAL ÚTILES PARA EL TRATAMIENTO DE CIERTAS CLASES DE CÁNCERES QUE SON RESISTENTES A LOS TRATAMIENTOS CON FÁRMACOS CONVENCIONALES,DEBIDO A QUE SE MUESTRA QUE ESTOS CÁNCERES SIGUEN SIENDO SENSIBLES A LOS COMPUESTOS DE LA INVENCIÓN.
PA20088807801A 2007-12-14 2008-12-12 Inhibidores de cinesina como productos terapeuticos para el cancer PA8807801A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1396607P 2007-12-14 2007-12-14

Publications (1)

Publication Number Publication Date
PA8807801A1 true PA8807801A1 (es) 2009-07-23

Family

ID=40328566

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20088807801A PA8807801A1 (es) 2007-12-14 2008-12-12 Inhibidores de cinesina como productos terapeuticos para el cancer

Country Status (30)

Country Link
US (2) US8252832B2 (es)
EP (1) EP2229170B1 (es)
JP (1) JP5501976B2 (es)
KR (1) KR20100098394A (es)
CN (1) CN101939005B (es)
AR (1) AR069676A1 (es)
AU (1) AU2008337570B2 (es)
BR (1) BRPI0821248A2 (es)
CA (1) CA2708822A1 (es)
CL (1) CL2008003707A1 (es)
CO (1) CO6290651A2 (es)
CR (1) CR11412A (es)
DO (1) DOP2010000175A (es)
EA (1) EA018014B1 (es)
EC (1) ECSP10010248A (es)
ES (1) ES2459442T3 (es)
GE (1) GEP20125647B (es)
GT (1) GT201000172A (es)
IL (1) IL205831A0 (es)
MA (1) MA31872B1 (es)
MY (1) MY150214A (es)
NI (1) NI201000091A (es)
NZ (1) NZ585142A (es)
PA (1) PA8807801A1 (es)
PE (1) PE20091451A1 (es)
SM (1) SMP201000095B (es)
TN (1) TN2010000204A1 (es)
TW (1) TW200930704A (es)
UY (1) UY31532A1 (es)
WO (1) WO2009077448A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8765817B1 (en) 2008-12-03 2014-07-01 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
US8349899B1 (en) 2008-12-03 2013-01-08 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
US8748626B2 (en) 2010-04-15 2014-06-10 Novartis Ag Oxazole and thiazole compounds as KSP inhibitors
JP2016516035A (ja) * 2013-03-15 2016-06-02 ノバルティス アーゲー 細胞増殖阻害剤およびそれらのコンジュゲート
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
AU2016282723B2 (en) * 2015-06-22 2021-09-23 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (ADCs) and antibody prodrug conjugates (APDCs) with enzymatically cleavable groups
CN105418527A (zh) * 2015-12-28 2016-03-23 青岛友诚高新技术有限公司 一种具有抗乳腺导管癌活性的化合物及其制备方法、用途
CN105646361B (zh) * 2016-02-17 2017-12-01 吉首大学 一种2,4,5‑三芳基咪唑型化合物及其制法和用途
IL310558A (en) 2016-12-21 2024-03-01 Bayer Pharma AG Drug-antibody conjugates with enzymatically cleavable groups
CN106668863B (zh) * 2017-02-21 2019-04-23 南方医科大学 靶向ktn1治疗皮肤鳞状细胞癌的药物
GB201706162D0 (en) * 2017-04-19 2017-05-31 Nat Univ Singapore Compounds
CN111954532A (zh) * 2018-04-13 2020-11-17 上海交通大学医学院附属瑞金医院 杂芳基酰胺类化合物的抗肿瘤多药耐药性、治疗癌症的用途和蛋白质-药物分子复合物
CN109646679A (zh) * 2019-01-28 2019-04-19 中国科学院长春应用化学研究所 铁离子螯合剂及其可药用盐的用途
CN111529526B (zh) * 2020-04-14 2021-04-23 广州领晟医疗科技有限公司 一种化合物在制备治疗急性胰腺炎的药物中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576221B2 (en) * 2004-06-18 2009-08-18 Novartis Vaccines And Diagnostics, Inc. Substituted imidazole derivatives
US7271271B2 (en) 2004-06-28 2007-09-18 Amgen Sf, Llc Imidazolo-related compounds, compositions and methods for their use
MY147188A (en) 2005-08-09 2012-11-14 Novartis Ag Substituted imidazole compounds as ksp inhibitors
CN101622247A (zh) 2007-01-05 2010-01-06 诺瓦提斯公司 作为驱动蛋白纺锤体蛋白抑制剂的咪唑衍生物

Also Published As

Publication number Publication date
SMAP201000095A (it) 2010-09-10
IL205831A0 (en) 2010-11-30
EA018014B1 (ru) 2013-04-30
CR11412A (es) 2010-06-30
GEP20125647B (en) 2012-09-25
KR20100098394A (ko) 2010-09-06
TW200930704A (en) 2009-07-16
BRPI0821248A2 (pt) 2015-06-16
ECSP10010248A (es) 2010-07-30
CN101939005B (zh) 2015-12-16
US20090239922A1 (en) 2009-09-24
JP2011506402A (ja) 2011-03-03
MY150214A (en) 2013-12-13
CL2008003707A1 (es) 2009-06-05
DOP2010000175A (es) 2010-06-30
US8664256B2 (en) 2014-03-04
AU2008337570B2 (en) 2012-04-05
GT201000172A (es) 2012-04-30
NI201000091A (es) 2011-03-15
JP5501976B2 (ja) 2014-05-28
ES2459442T3 (es) 2014-05-09
PE20091451A1 (es) 2009-10-19
NZ585142A (en) 2012-03-30
CA2708822A1 (en) 2009-06-25
MA31872B1 (fr) 2010-11-01
EP2229170A1 (en) 2010-09-22
US8252832B2 (en) 2012-08-28
UY31532A1 (es) 2009-08-03
CN101939005A (zh) 2011-01-05
SMP201000095B (it) 2011-09-09
EA201000900A1 (ru) 2011-02-28
AR069676A1 (es) 2010-02-10
WO2009077448A1 (en) 2009-06-25
TN2010000204A1 (en) 2011-11-11
EP2229170B1 (en) 2014-01-22
AU2008337570A1 (en) 2009-06-25
US20130012560A1 (en) 2013-01-10
CO6290651A2 (es) 2011-06-20

Similar Documents

Publication Publication Date Title
PA8807801A1 (es) Inhibidores de cinesina como productos terapeuticos para el cancer
CO2022016377A2 (es) Inhibidores de kras tricíclicos fusionados
DOP2019000020A (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
ECSP099445A (es) Quinazolinas para la inhibición de pdk1
NI201600058A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
CO2022004694A2 (es) Heterociclos bicíclicos como inhibidores de fgfr
GT200800202A (es) Quinazolinas para la inhibicion de pdk1
CL2008001743A1 (es) Uso de un compuesto derivado de quinazolina para tratar el cancer; uso del compuesto y de otro compuesto antineoplasico; compuestos derivados de quinazolina; y composicion farmaceutica que los comprende.
DOP2021000017A (es) Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos
CL2020002719A1 (es) Moduladores de nlrp3
ECSP20061378A (es) COMPUESTOS DIÓLICOS DE AMINOPIRAZINA COMO INHIBIDORES DE PI3K-gamma
CL2019000661A1 (es) Inhibidores de dopamina–b–hidroxilasa penetrantes de la barrera hematoencefálica.
UY35136A (es) Métodos para tratar el cáncer de ovario con antagonistas de dll4.
DOP2018000238A (es) Inhibidores del potenciador del homólogo zeste 2
BR112017014793A2 (pt) regime de dosagem para antagonistas de madcam
UY39477A (es) Compuestos espiro heterocíclicos y métodos de uso
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
CL2021001656A1 (es) Compuestos de imidazopiridina e imidazopiridina y sus usos.
ECSP22098041A (es) Inhibidores alostéricos de egfr y métodos de uso de estos
CO2020013834A2 (es) Ciertos compuestos de pladienolida y métodos de uso
BR112017022296A2 (pt) métodos para tratar câncer
CL2023000121A1 (es) Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrófilas
CU20100121A7 (es) Inhibidores de cinesina como productos terapéuticos para el cáncer
CO2019001967A2 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
AR099931A1 (es) Combinaciones de agentes terapéuticos contra cáncer